AI Predicts Breast Cancer Recurrence with New Tool

A novel artificial intelligence tool developed at New York University is set to significantly alter the understanding of breast cancer recurrence risk. This technology integrates digital images of tumor tissue with fundamental clinical information to provide quicker and more precise guidance for patients and physicians.

The AI system analyzes routine digitized tumor slides, identifying subtle patterns potentially invisible to the human eye. Combined with data such as tumor stage and patient age, it generates a score estimating the likelihood of cancer returning, offering a compelling alternative to traditional genomic tests.

Researchers evaluated the system using data from over 3,500 patients across seven countries. The AI demonstrated strong performance in accurately categorizing patients by risk, including for challenging subtypes like triple-negative and HER2-positive breast cancer.

This innovative approach offers substantial advantages, including rapid results available within hours, a stark contrast to the weeks typically required for genomic testing. Furthermore, it reduces costs by utilizing existing slides and preserves valuable tissue samples for future analysis.

The system's ability to provide clearer risk stratification may lead to more confident treatment decisions, potentially benefiting patients by preventing unnecessary chemotherapy or ensuring adequate treatment. The research, published in Nature Communications, represents a significant step toward personalized medicine and could eventually be adapted for other diseases.